Merck (MRK) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Merck (MRK) has outperformed Pfizer (PFE) over the past year, gaining 36.8% versus a gain of 9.4%. Over five years, MRK leads with a +68.9% price change compared with -49.3% for PFE. Merck is the larger company by market cap ($329.65 billion vs $156.18 billion), about 2.1 times the size.
On valuation, Pfizer trades at a lower forward P/E (9.3x vs 14.9x for Merck). Pfizer offers the higher dividend yield (7.85% vs 2.51%). Merck converts more of its revenue into profit, with a net margin of 28.1% versus 12.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRK | PFE |
|---|---|---|
| Share price | $133.72 | $27.40 |
| Market cap | $329.65B | $156.18B |
| 1-day change | +0.69% | -0.51% |
| YTD return | +27.04% | +10.04% |
| 1-year return | +36.78% | +9.42% |
| 5-year return | +68.92% | -49.26% |
| P/E ratio (TTM) | 135.07 | 39.14 |
| Forward P/E | 14.92 | 9.28 |
| EPS (TTM) | $0.99 | $0.70 |
| Dividend yield | 2.51% | 7.85% |
| Annual dividend | $3.36 | $2.15 |
| Revenue (latest FY) | $65.01B | $62.58B |
| Revenue growth (YoY) | +1.31% | -1.65% |
| Net income (latest FY) | $18.25B | $7.77B |
| Gross margin | 74.80% | 74.33% |
| Net margin | 28.08% | 12.42% |
| 52-week high | $156.92 | $31.44 |
| 52-week low | $96.06 | $23.62 |
| Distance from 52-week high | -14.78% | -12.85% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +20.80% | +10.29% |
| Average volume | 9.81M | 33.52M |
| Shares outstanding | 2.47B | 5.70B |
| Employees | 73,000 | 75,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Merck is about 2.1 times larger than Pfizer by market value ($329.65B vs $156.18B).
- MRK has outperformed PFE by 27.4 percentage points over the past year.
- Merck trades at a higher earnings multiple (135.1x vs 39.1x trailing P/E).
- Pfizer offers a meaningfully higher dividend yield (7.85% vs 2.51%).
- Merck is more profitable, keeping 28.1 cents of every revenue dollar as net income versus 12.4 cents for Pfizer.
About Merck
MRK stock →Merck & Co., Inc. operates as a healthcare company worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
MRK vs PFE FAQ
Which is bigger, Merck or Pfizer?
Merck (MRK) is larger, with a market capitalization of $329.65B compared with $156.18B for Pfizer (PFE).
Which stock has performed better over the past year, MRK or PFE?
MRK returned +36.78% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MRK or PFE?
PFE has the lower trailing P/E at 39.1, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Merck or Pfizer?
Pfizer has the higher yield at 7.85%, compared with 2.51% for Merck.
Are Merck and Pfizer in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.